## Clinical Diagnosis: Gestational Hypertension — Antihypertensive Escalation **Key Point:** This patient has gestational hypertension (new-onset HTN ≥140/90 mmHg after 20 weeks, without proteinuria or systemic features) that is inadequately controlled on methyldopa monotherapy. At 32 weeks with BP 150/100 mmHg, the appropriate step is **outpatient antihypertensive intensification** by adding a second agent — not hospitalization, not switching monotherapy, and not aspirin. ### Diagnostic Classification | Condition | BP Criteria | Proteinuria | Systemic Features | Management at 32 wks | |-----------|------------|-------------|-------------------|----------------------| | **Gestational HTN** | ≥140/90 (new onset after 20 wks) | Absent | None | Outpatient dual therapy | | **Preeclampsia** | ≥140/90 + proteinuria | ≥300 mg/24h | May have | Delivery planning, MgSO₄ | | **Severe preeclampsia** | ≥160/110 OR end-organ damage | Any | Yes | Urgent delivery, IV antihypertensives | **High-Yield (ACOG Practice Bulletin 203):** Gestational hypertension without proteinuria or severe-range BP at <34 weeks is managed with outpatient antihypertensive escalation. Hospitalization is reserved for severe-range BP (≥160/110 mmHg) or development of preeclampsia features. ### Rationale for Each Option **Option A — Correct:** Adding amlodipine (a dihydropyridine calcium channel blocker) to methyldopa is a well-established dual-therapy regimen in pregnancy. Amlodipine has an excellent safety profile in pregnancy with no documented teratogenicity. Rechecking BP in 1–2 weeks is appropriate for outpatient gestational hypertension without severe features. This aligns with ACOG and WHO recommendations for stepwise antihypertensive escalation. **Option B — Incorrect:** Low-dose aspirin (75–150 mg/day) is indicated for **primary prevention** of preeclampsia in high-risk women (e.g., prior preeclampsia, chronic hypertension, multiples, renal disease) when initiated before 16 weeks of gestation. It has no role in treating established gestational hypertension at 32 weeks. Adding aspirin at this stage does not lower BP and is not guideline-recommended for this indication. **Option C — Incorrect:** Switching to labetalol as monotherapy is not the preferred approach when methyldopa is partially effective. The standard practice is to **add** a second agent rather than switch, to achieve additive BP control. Labetalol is a safe and effective first-line agent in pregnancy, but replacing rather than augmenting therapy is suboptimal when partial response exists. **Option D — Incorrect:** IV hydralazine is reserved for **acute severe hypertension** (BP ≥160/110 mmHg) requiring urgent BP reduction to prevent maternal stroke or eclampsia. This patient's BP of 150/100 mmHg is in the non-severe range with normal labs and fetal status; inpatient admission and IV therapy are not indicated. ### BP Targets in Pregnancy Per ACOG PB 203 and CHIPS Trial (Magee et al., NEJM 2015): The target BP in non-severe gestational hypertension is **130–150/80–100 mmHg**. Aggressive over-treatment targeting <130/80 mmHg is associated with reduced uteroplacental perfusion and increased risk of fetal growth restriction — a critical distinction from non-pregnant hypertension management. **Clinical Pearl:** In pregnancy, antihypertensive escalation follows a stepwise additive approach: methyldopa → add amlodipine or labetalol → add hydralazine (oral) → IV therapy only for severe-range BP. Switching monotherapy is less preferred over combination therapy when partial control is achieved. **High-Yield Mnemonic — Safe antihypertensives in pregnancy:** **LAMB** — **L**abetalol, **A**mlodipine, **M**ethyldopa, **B**eta-blockers (atenolol avoided); ACE inhibitors and ARBs are **contraindicated** in pregnancy.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.